search
Back to results

ACH04 to Assess the Safety and Tolerability in Healthy Adults Subjects

Primary Purpose

Diarrhea

Status
Completed
Phase
Phase 1
Locations
Brazil
Study Type
Interventional
Intervention
ACH04
Sponsored by
Ache Laboratorios Farmaceuticos S.A.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diarrhea focused on measuring safety, tolerability, rising multiple doses, ACH04, adult, male

Eligibility Criteria

18 Years - 50 Years (Adult)MaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Subjects will be healthy males subjects between 18 and 50 years of age;
  • Subjects must be in good healthy as determined by a medical history, physical examination and clinical laboratory evaluations;
  • Subjects will, prior to any study related activities, have given their written informed consent to participate in the study and to abide by the stdy restrictions.

Exclusion Criteria:

  • Subjects with hypersensitivity known to Psidium guajava L. or history of serious adverse events;
  • Subjects who have a significant history of alcoholism or drug/chemical abuse;
  • Subjects who have body mass index < 18 or > 30;
  • Subjects who have received any medications that is known to have a toxic potential well defined in large organs within the past 3 months prior the study start;
  • Subjets who doesn´t agree to use, for the duration of the study, a barrier contraceptive;
  • Subjects who were hospitalized for any reason in the six week prior the study start;
  • Subjects who, in the opinion of the investigator, should not participate in the study, including subjects suspected for whatever reason of not being able to comply with the requirements of the protocol;
  • Subjects who are participating in a clinical trial or have participated in a clinical study involving administration of an investigational drug, within one year;
  • Subjects who are relatives of employees from the sponsor and the site, respectively;
  • Subjects with, or with a history of, any clinically significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychiatric, respiratory, metabolic, endocrine, haematological, dermatological or other major disorders as determined by the Investigator;
  • Any finding of clinical observation (anamnesis and physical evaluation), laboratory abnormality, who in the investigator opinion, may jeopardize the subjects or interfere with the study goals.

Sites / Locations

  • UNIFAC

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

ACH04

Arm Description

Dosage: 1 capsule, PO, 24/24h for 10 days.

Outcomes

Primary Outcome Measures

Evaluate the safety of rising multiple doses of ACH04
Evaluate the occurrence of adverse events, Assess safety through laboratory tests and Assess safety through electrocardiogram

Secondary Outcome Measures

Full Information

First Posted
May 3, 2011
Last Updated
October 27, 2016
Sponsor
Ache Laboratorios Farmaceuticos S.A.
search

1. Study Identification

Unique Protocol Identification Number
NCT02949089
Brief Title
ACH04 to Assess the Safety and Tolerability in Healthy Adults Subjects
Official Title
An Open Label, Dose Escalation Study of ACH04 to Assess the Safety and Tolerability in Healthy Adults Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
October 2016
Overall Recruitment Status
Completed
Study Start Date
January 2013 (undefined)
Primary Completion Date
September 2014 (Actual)
Study Completion Date
September 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ache Laboratorios Farmaceuticos S.A.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study intends to provide information on the safety and tolerability of repeated oral doses of ACH04. A phase I, single-center, first in human, open-label, dose escalation study of ACH04 to assess the safety and tolerability in healthy adults subjects is selected to best address the study goals.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diarrhea
Keywords
safety, tolerability, rising multiple doses, ACH04, adult, male

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
ACH04
Arm Type
Experimental
Arm Description
Dosage: 1 capsule, PO, 24/24h for 10 days.
Intervention Type
Drug
Intervention Name(s)
ACH04
Intervention Description
The subjects will receive the study medication in each group
Primary Outcome Measure Information:
Title
Evaluate the safety of rising multiple doses of ACH04
Description
Evaluate the occurrence of adverse events, Assess safety through laboratory tests and Assess safety through electrocardiogram
Time Frame
up to 39 days

10. Eligibility

Sex
Male
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
50 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Subjects will be healthy males subjects between 18 and 50 years of age; Subjects must be in good healthy as determined by a medical history, physical examination and clinical laboratory evaluations; Subjects will, prior to any study related activities, have given their written informed consent to participate in the study and to abide by the stdy restrictions. Exclusion Criteria: Subjects with hypersensitivity known to Psidium guajava L. or history of serious adverse events; Subjects who have a significant history of alcoholism or drug/chemical abuse; Subjects who have body mass index < 18 or > 30; Subjects who have received any medications that is known to have a toxic potential well defined in large organs within the past 3 months prior the study start; Subjets who doesn´t agree to use, for the duration of the study, a barrier contraceptive; Subjects who were hospitalized for any reason in the six week prior the study start; Subjects who, in the opinion of the investigator, should not participate in the study, including subjects suspected for whatever reason of not being able to comply with the requirements of the protocol; Subjects who are participating in a clinical trial or have participated in a clinical study involving administration of an investigational drug, within one year; Subjects who are relatives of employees from the sponsor and the site, respectively; Subjects with, or with a history of, any clinically significant neurological, gastrointestinal, renal, hepatic, cardiovascular, psychiatric, respiratory, metabolic, endocrine, haematological, dermatological or other major disorders as determined by the Investigator; Any finding of clinical observation (anamnesis and physical evaluation), laboratory abnormality, who in the investigator opinion, may jeopardize the subjects or interfere with the study goals.
Facility Information:
Facility Name
UNIFAC
City
Fortaleza
State/Province
Ceará
ZIP/Postal Code
60160140
Country
Brazil

12. IPD Sharing Statement

Learn more about this trial

ACH04 to Assess the Safety and Tolerability in Healthy Adults Subjects

We'll reach out to this number within 24 hrs